Acurx Pharmaceuticals Inc
Company Profile
Business description
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Contact
259 Liberty Avenue
Staten IslandNY10305
USAT: +1 917 533-1469
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
Weak investor sentiment for cheap ASX
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,016.10 | 57.40 | 0.64% |
| CAC 40 | 8,298.97 | 236.66 | 2.94% |
| DAX 40 | 24,934.34 | 532.64 | 2.18% |
| Dow JONES (US) | 49,298.25 | 356.35 | 0.73% |
| FTSE 100 | 10,452.91 | 233.80 | 2.29% |
| HKSE | 26,213.78 | 315.17 | 1.22% |
| NASDAQ | 25,326.13 | 258.33 | 1.03% |
| Nikkei 225 | 59,513.12 | 228.20 | 0.38% |
| NZX 50 Index | 13,145.19 | 109.49 | 0.84% |
| S&P 500 | 7,259.22 | 58.47 | 0.81% |
| S&P/ASX 200 | 8,793.60 | 58.60 | 0.67% |
| SSE Composite Index | 4,160.17 | 48.01 | 1.17% |